Litcius/Paper detail

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen, Haili Tang, Charlene McDanal, Kshitij Wagh, Will Fischer, James Theiler, Hyejin Yoon, Dapeng Li, Barton F. Haynes, Kevin O. Sanders, S. Gnanakaran, Nicolas Hengartner, Rolando Pajón, Gale Smith, Gregory M. Glenn, Bette Korber, David C. Montefiori

2021Cell Host & Microbe395 citationsDOIOpen Access PDF

Topics & Concepts

Spike ProteinBiologyAntibodySpike (software development)NeutralizationVirologyMonoclonal antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Neutralizing antibodyCoronavirus disease 2019 (COVID-19)Immune systemImmunologyDiseaseMedicineInfectious disease (medical specialty)EconomicsPathologyManagementSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines | Litcius